InflaRx N.V. (IFRX)
NASDAQ: IFRX · Real-Time Price · USD
0.8070
-0.0081 (-0.99%)
At close: Aug 8, 2025, 4:00 PM
0.8165
+0.0095 (1.18%)
After-hours: Aug 8, 2025, 7:53 PM EDT
InflaRx Revenue
InflaRx had revenue of 39.43K EUR in the quarter ending June 30, 2025, with 520.29% growth. This brings the company's revenue in the last twelve months to 162.83K, up 54.36% year-over-year. In the year 2024, InflaRx had annual revenue of 165.79K with 162.79% growth.
Revenue (ttm)
162.83K EUR
Revenue Growth
+54.36%
P/S Ratio
260.56
Revenue / Employee
2,200 EUR
Employees
74
Market Cap
54.67M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 165.79K | 102.70K | 162.79% |
Dec 31, 2023 | 63.09K | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
IFRX News
- 1 day ago - InflaRx Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 8 days ago - InflaRx to Report Second Quarter 2025 Results on August 7, 2025 - GlobeNewsWire
- 4 weeks ago - InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement - GlobeNewsWire
- 2 months ago - InflaRx Ends Lead Asset Development After Failed Study For Rare And Painful Skin Disease - Benzinga
- 2 months ago - InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma Gangrenosum - GlobeNewsWire
- 2 months ago - InflaRx to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - InflaRx Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 3 months ago - InflaRx to Report First Quarter 2025 Results on May 7, 2025 - GlobeNewsWire